{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:40:34Z","timestamp":1773801634431,"version":"3.50.1"},"reference-count":105,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2836,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The amyloid hypothesis\u2014the leading mechanistic theory of Alzheimer's disease\u2014states that an imbalance in production or clearance of amyloid \u03b2 (A\u03b2) results in accumulation of A\u03b2 and triggers a cascade of events leading to neurodegeneration and dementia. The number of persons with Alzheimer's disease is expected to triple by mid-century. If steps are not taken to delay the onset or slow the progression of Alzheimer's disease, the economic and personal tolls will be immense. Different classes of potentially disease-modifying treatments that interrupt early pathological events (ie, decreasing production or aggregation of A\u03b2 or increasing its clearance) and potentially prevent downstream events are in phase II or III clinical studies. These include immunotherapies; secretase inhibitors; selective A\u03b2<jats:sub>42<\/jats:sub>-lowering agents; statins; anti-A\u03b2 aggregation agents; peroxisome proliferator-activated receptor-gamma agonists; and others. Safety and serious adverse events have been a concern with immunotherapy and \u03b3-secretase inhibitors, though both continue in clinical trials. Anti-amyloid disease-modifying drugs that seem promising and have reached phase III clinical trials include those that selectively target A\u03b2<jats:sub>42<\/jats:sub>production (eg, tarenflurbil), enhance the activity of \u03b1-secretase (eg, statins), and block A\u03b2 aggregation (eg, transiposate).<\/jats:p>","DOI":"10.1017\/s1092852900020629","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:53:05Z","timestamp":1470113585000},"page":"113-123","source":"Crossref","is-referenced-by-count":20,"title":["Alzheimer's Disease:<i>Progress in the Development of Anti-amyloid Disease-Modifying Therapies<\/i>"],"prefix":"10.1017","volume":"12","author":[{"given":"Daniel D.","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900020629_ref047","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304824200"},{"key":"S1092852900020629_ref072","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.1.197"},{"key":"S1092852900020629_ref061","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(04)81970-5"},{"key":"S1092852900020629_ref012","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00008"},{"key":"S1092852900020629_ref066","first-page":"222","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics"},{"key":"S1092852900020629_ref032","doi-asserted-by":"publisher","DOI":"10.1038\/35050110"},{"key":"S1092852900020629_ref030","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.11.1186"},{"key":"S1092852900020629_ref024","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.3.310"},{"key":"S1092852900020629_ref022","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis","volume":"169","author":"Lanct\u00f4t","year":"2003","journal-title":"CMAJ"},{"key":"S1092852900020629_ref059","first-page":"95","article-title":"NC-531 Neurochem","volume":"5","author":"Geerts","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"S1092852900020629_ref020","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"S1092852900020629_ref089","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200000001-00006"},{"key":"S1092852900020629_ref029","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.317"},{"key":"S1092852900020629_ref081","first-page":"234","article-title":"Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group","volume":"24","author":"Filip","year":"1999","journal-title":"J Psychiatry Neurosci"},{"key":"S1092852900020629_ref017","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1834302100"},{"key":"S1092852900020629_ref033","doi-asserted-by":"publisher","DOI":"10.1038\/35050116"},{"key":"S1092852900020629_ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68542-5"},{"key":"S1092852900020629_ref013","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.11.1764"},{"key":"S1092852900020629_ref042","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000198762.41312.E1"},{"key":"S1092852900020629_ref027","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.11.2003"},{"key":"S1092852900020629_ref011","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.1_Suppl_1.S53"},{"key":"S1092852900020629_ref075","unstructured":"Fiorucci S , Santucci L , Sardina M , et al. Effect of HCT1026, a nitric oxide (NO) releasing derivative of flurbiprofen, on gastrointestinal mucosa: a double blind placebo-controlled endoscopic study. Abstract presented at: Digestive Disease Week. May 17-22, 2003; Orlando, FL."},{"key":"S1092852900020629_ref045","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1495"},{"key":"S1092852900020629_ref006","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.612"},{"key":"S1092852900020629_ref009","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140248"},{"key":"S1092852900020629_ref044","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2005.06.037"},{"key":"S1092852900020629_ref039","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(04)00182-5"},{"key":"S1092852900020629_ref037","first-page":"35","article-title":"Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease","volume":"6","author":"Pollack","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"S1092852900020629_ref090","doi-asserted-by":"publisher","DOI":"10.1038\/nm1239"},{"key":"S1092852900020629_ref043","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-9961(03)00104-9"},{"key":"S1092852900020629_ref040","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308126101"},{"key":"S1092852900020629_ref057","first-page":"28","article-title":"Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy","volume":"8","author":"Gervais","year":"2001","journal-title":"Amyloid"},{"key":"S1092852900020629_ref026","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"S1092852900020629_ref041","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000167360.27670.29"},{"key":"S1092852900020629_ref003","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.88.9.1337"},{"key":"S1092852900020629_ref004","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.23.100901.140525"},{"key":"S1092852900020629_ref036","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148590.39911.DF"},{"key":"S1092852900020629_ref076","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(99)00028-7"},{"key":"S1092852900020629_ref058","unstructured":"Garceau D , Gurbindo C , Laurin J . Safety, tolerability and pharmacokinetic profile of Alzhemed\u2122, an anti-amyloid agent for Alzheimer's disease, in healthy subjects. Presented at: the annual meeting of the International Geneva\/Springfield Symposium on Advances in Alzheimer Therapy. April 3-6, 2002; Geneva, Switzerland."},{"key":"S1092852900020629_ref005","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.17.6.206"},{"key":"S1092852900020629_ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.12.015"},{"key":"S1092852900020629_ref084","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.9.1154"},{"key":"S1092852900020629_ref063","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2004-6103"},{"key":"S1092852900020629_ref018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2005.11.003"},{"key":"S1092852900020629_ref019","volume-title":"Working to Change the Course of Alzheimer's Disease","year":"2006"},{"key":"S1092852900020629_ref023","doi-asserted-by":"publisher","DOI":"10.1159\/000008243"},{"key":"S1092852900020629_ref064","first-page":"193","article-title":"Colostrinin proline-rich polypeptide complex from ovine colostrum\u2013a long-term study of its efficacy in Alzheimer's disease","volume":"8","author":"Leszek","year":"2002","journal-title":"Med Sci Monit"},{"key":"S1092852900020629_ref015","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000189033.35579.2d"},{"key":"S1092852900020629_ref086","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050151"},{"key":"S1092852900020629_ref014","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000173837.82820.9f"},{"key":"S1092852900020629_ref065","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh452"},{"key":"S1092852900020629_ref001","first-page":"146","article-title":"\u00dcber eine eigenartige Erkrankung der Hirnrinde","volume":"64","author":"Alzheimer","year":"1907","journal-title":"Allgemeine Zeitschrift fur Psychiatrie"},{"key":"S1092852900020629_ref038","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311652200"},{"key":"S1092852900020629_ref008","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.5.674"},{"key":"S1092852900020629_ref101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500466102"},{"key":"S1092852900020629_ref031","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"S1092852900020629_ref016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"S1092852900020629_ref053","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.10.1439"},{"key":"S1092852900020629_ref062","first-page":"78","article-title":"Technology evaluation: Colostrinin, ReGen","volume":"7","author":"Rattray","year":"2005","journal-title":"Curr Opin Molecular Therap"},{"key":"S1092852900020629_ref025","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.481"},{"key":"S1092852900020629_ref046","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317527"},{"key":"S1092852900020629_ref035","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"S1092852900020629_ref002","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.8.1119"},{"key":"S1092852900020629_ref070","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.21.2819"},{"key":"S1092852900020629_ref048","unstructured":"Golde TE , Eriksen J , Nicolle M , et al. Selective Abeta42 modifying agents: effects on Abeta deposition and behavior in Tg2576 mice. Paper presented at: annual meeting of the International Conference on Alzheimer's Disease and Related Disorders. July 18, 2004; Philadelphia, Penn."},{"key":"S1092852900020629_ref092","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.24.2947"},{"key":"S1092852900020629_ref050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jalz.2006.05.316","article-title":"Efficacy and safety of MPC-7969 (R-flurbiprofen), a selective A\u03b242\u2013lowering agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study (abstract 04-03-08)","volume":"2","author":"Wilcock","year":"2006","journal-title":"Alzheimer's and Dementia"},{"key":"S1092852900020629_ref034","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404866101"},{"key":"S1092852900020629_ref051","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03155-X"},{"key":"S1092852900020629_ref074","first-page":"CD003673","article-title":"Indomethacin for the treatment of Alzheimer's disease patients","author":"Tabet","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852900020629_ref052","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.2.223"},{"key":"S1092852900020629_ref077","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2004.12.026"},{"key":"S1092852900020629_ref054","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2005.09.018"},{"key":"S1092852900020629_ref056","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.5.753"},{"key":"S1092852900020629_ref060","doi-asserted-by":"crossref","unstructured":"Aisen P , Mehran M , Poole R , et al. Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Paper presented at: annual meeting of the International Conference on Alzheimer's Disease and Related Disorders. July 18, 2004; Philadelphia, Penn.","DOI":"10.1016\/S0197-4580(04)80065-4"},{"key":"S1092852900020629_ref094","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.2.295"},{"key":"S1092852900020629_ref067","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2006.05.1249"},{"key":"S1092852900020629_ref068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010178"},{"key":"S1092852900020629_ref069","doi-asserted-by":"publisher","DOI":"10.1159\/000078501"},{"key":"S1092852900020629_ref071","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.1.66"},{"key":"S1092852900020629_ref073","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1609"},{"key":"S1092852900020629_ref079","unstructured":"National Institutes of Health Web site. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. NIH News. December, 20, 2004. Available at: http:\/\/www.nih.gov\/news\/pr\/dec2004\/od-20.htm. Accessed August 3, 2006."},{"key":"S1092852900020629_ref080","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20774"},{"key":"S1092852900020629_ref082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361704"},{"key":"S1092852900020629_ref083","doi-asserted-by":"publisher","DOI":"10.1016\/S1543-5946(04)90017-7"},{"key":"S1092852900020629_ref085","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G280"},{"key":"S1092852900020629_ref088","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2004.45.Suppl.28"},{"key":"S1092852900020629_ref078","unstructured":"Derwent Information Ltd Web site. Nitroflurbiprofen (oral), NicOx page. April 26, 2004. Available at: http:\/\/www.bizcharts.com\/pdfs\/IDdbCox2Record.pdf Accessed August 3, 2006."},{"key":"S1092852900020629_ref091","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000143318.70292.47"},{"key":"S1092852900020629_ref049","unstructured":"Galasko D , Graff-Radford N , Murphy MP , et al. Safety, tolerability, pharmacokinetics and A\u03b2 levels following short-term administration of R-flurbiprofen in healthy elderly individuals: a phase I study. Paper presented at: the 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, Penn; July 18, 2004."},{"key":"S1092852900020629_ref095","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1007"},{"key":"S1092852900020629_ref096","unstructured":"Clinical Trials Web stie ALADDIN study \u2013 Phase III: antigonadotropin-leuprolide in Alzheimer's disease drug investigation (VP-AD-301). Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00231946?order=1. Accessed August 3, 2006."},{"key":"S1092852900020629_ref010","first-page":"119","volume-title":"Trial Designs and Outcomes in Dementia Therapeutic Research","author":"Ballard","year":"2006"},{"key":"S1092852900020629_ref097","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4386-y"},{"key":"S1092852900020629_ref103","unstructured":"ClinicalTrials Web stie Valproate in dementia (VALID). Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00071721?order=1. Accessed November 3, 2006."},{"key":"S1092852900020629_ref098","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311993200"},{"key":"S1092852900020629_ref099","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00153-9"},{"key":"S1092852900020629_ref105","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000191420.61260.a8"},{"key":"S1092852900020629_ref028","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.676"},{"key":"S1092852900020629_ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2006.05.919"},{"key":"S1092852900020629_ref093","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.20.2651"},{"key":"S1092852900020629_ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.mibio.2003.09.010"},{"key":"S1092852900020629_ref087","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-2-200507190-00014"},{"key":"S1092852900020629_ref055","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020018"},{"key":"S1092852900020629_ref100","doi-asserted-by":"publisher","DOI":"10.1021\/bi035627j"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900020629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T17:53:55Z","timestamp":1656957235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900020629\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S1092852900020629"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900020629","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}